Peter Hardwick | Association for Accessible Medicines
AAM All Access Podcast - AAM CEO Dan Leonard convenes industry and policy experts to explore why the Inflation Reduction Act (f/k/a Build Back Better) reduces generic and biosimilar competition.

Peter Hardwick

AAM Board Member
U.S. President and CEO Apotex Corp.
Peter Hardwick
Peter Hardwick
Apotex Corp.

Peter Hardwick is U.S. President and CEO of Apotex Corp.

Peter is responsible for Apotex's global commercial strategy for all generic market segments. He joined Apotex as Director of Marketing Canada and took on expanded roles within the Canadian market.

Peter has 27 years of Pharma experience in sales and marketing, international management, and held P&L responsibility of core countries within a Global Pharmaceutical company. He has both brand and generic experience, including five years abroad based in Basel Switzerland working for Mepha Inc., which specialized in branded generics.​​

Peter has a Bachelor of Science in Biology from St. Mary's University and is a graduate of the Ashridge Executive Management Program in London, UK.​

Latest Tweets

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.